Ivabradine Cf (Ivabradine Hydrochloride)

Ivabradine acts on the cardiac If current to control heart rate, making it useful in several cardiovascular conditions.

• Chronic stable angina: reduces the frequency of angina episodes and improves exercise tolerance.
• Heart failure with reduced ejection fraction: lowers heart rate, which can improve functional capacity and decrease hospitalisations.
• Symptomatic angina in patients intolerant to beta‑blockers: provides an alternative means of heart‑rate reduction.

• Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which slows spontaneous depolarisation. By reducing the pacemaker activity, the drug lowers heart rate without compromising myocardial contractility or blood pressure, thereby decreasing myocardial oxygen demand in patients with angina or heart failure.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects

• Bradycardia: heart rate below the intended therapeutic range.
• Visual disturbances (phosphenes): transient luminous phenomena.
• Headache: mild to moderate intensity.
• Dizziness or light‑headedness.
• Fatigue or general weakness.
• Blurred vision.

Serious or Rare Side Effects

• Symptomatic severe bradycardia requiring medical attention.
• Atrial fibrillation or other significant arrhythmias.
• Severe hypotension leading to syncope.
• High‑grade atrioventricular block.
• Vision loss or persistent visual impairment.
• Life‑threatening allergic reactions (anaphylaxis).

Before initiating ivabradine, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate baseline heart rate and rhythm.
• Concomitant bradycardic agents: avoid or adjust dose when used with beta‑blockers, digoxin, or calcium‑channel blockers.
• CYP3A4 inhibitors: avoid strong inhibitors that may increase ivabradine exposure.
• Hepatic impairment: use with caution in moderate to severe liver disease.
• Pregnancy and lactation: safety not established; avoid unless clearly needed.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ivabradine may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels.
• Other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem): risk of excessive bradycardia.
• AV‑nodal blocking agents: may precipitate atrioventricular block.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment.
• Antihypertensive agents: monitor blood pressure for additive effects.
• Diuretics: watch for electrolyte disturbances that could affect cardiac conduction.
• Other anti‑anginal medications: assess overall heart‑rate control.